Etaracizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Etaracizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target alpha-v beta-3 integrin
Clinical data
Trade names Abegrin
Legal status
?
Identifiers
CAS number 892553-42-3 N
ATC code None
UNII 41W9MFI160 YesY
KEGG D09342 YesY
Chemical data
Formula C6392H9908N1732O1996S42 
Mol. mass 144.3 kDa
 N (what is this?)  (verify)

Etaracizumab (also known as etaratuzumab[citation needed], MEDI-522, trade name Abegrin) is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer,[1] ovarian cancer[2] and various other types of cancer.[3] It is manufactured by MedImmune.[1]

Adverse drug effects[edit]

References[edit]

  1. ^ a b Statement On A Nonproprietary Name Adopted By The Usan Council: Etaracizumab
  2. ^ Landen, CN; Kim, TJ; Lin, YG; Merritt, WM; Kamat, AA; Han, LY; Spannuth, WA; Nick, AM; Jennnings, NB (2008). "Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer". Neoplasia 10 (11): 1259–67. PMC 2570602. PMID 18953435. 
  3. ^ Delbaldo, C; Raymond, E; Vera, K; Hammershaimb, L; Kaucic, K; Lozahic, S; Marty, M; Faivre, S (2008). "Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors". Investigational new drugs 26 (1): 35–43. doi:10.1007/s10637-007-9077-0. PMID 17876527.